COMMUNIQUÉS West-GlobeNewswire

ERPSI Wins $6.6M Contract to Provide TSA with Application Production Support

18/07/2018 - 19:40

ARLINGTON, Va., July 18, 2018 (GLOBE NEWSWIRE) -- The US Department of Homeland Security (DHS) Transportation Security Administration’s (TSA) Applications Development Division (ADD) has awarded Enterprise Resource [...]

William Hartman, CEO of Premier Biomedical, Returns to Uptick Newswire’s “Stock Day” Podcast

18/07/2018 - 19:17

PHOENIX, July 18, 2018 (GLOBE NEWSWIRE) -- William Hartman, CEO of Premier Biomedical Inc. (OTC PINK:BIEI) ("the Company") joined Everett Jolly on Uptick Newswire’s “Stock Day” podcast. Premier Biomedical currently [...]

Information concerning the total number of voting rights and shares

18/07/2018 - 18:01

Information concerning the total number of voting rights and shares, provided pursuant to article L. 233-8 II of the Code de commerce (the French Commercial Code) and article 223-16 of the Règlement général de l' [...]

Informations relatives au nombre total de droits de vote et d'actions

18/07/2018 - 18:01

Informations relatives au nombre total de droits de vote et d'actions prévues par l'article L. 233-8 II du Code de commerce et l'article 223-16 du Règlement général de l'Autorité des Marchés Financiers Sanofi Société [...]

VALNEVA :Transfert à Oddo BHF du contrat de liquidité initialement conclu avec Natixis

18/07/2018 - 17:46

Transfert à Oddo BHF du contrat de liquidité de Valneva initialement conclu avec Natixis Nantes, France, 18 juillet 2018 - Valneva SE ("Valneva" ou "le Groupe"), société de biotechnologie dédiée au développement, à la [...]

Novartis Kisqali® now first and only CDK4/6 inhibitor indicated in US as first-line therapy specifically for premenopausal women; and as initial therapy with fulvestrant in postmenopausal women

18/07/2018 - 17:31

Kisqali is now the only CDK4/6 inhibitor indicated in combination with an aromatase inhibitor as first-line treatment for pre-, peri- or postmenopausal women with HR+/HER2- advanced breast cancer in the US[1] Kisqali is [...]

JetBlue Airways to Implement ClimaCell’s New HyperCast Aviation Microweather Software to Increase Safety and Efficiency

18/07/2018 - 17:11

New HyperCast Aviation solution designed specifically for airlines and airport operations teams BOSTON, July 18, 2018 (GLOBE NEWSWIRE) -- ClimaCell Ⓡ , the microweather™ technology company that finds and forecasts [...]

Tabula Rasa Healthcare to Announce Second Quarter 2018 Operating Results and Host Conference Call on Tuesday, August 7, 2018

18/07/2018 - 16:00

MOORESTOWN, N.J., July 18, 2018 (GLOBE NEWSWIRE) -- Tabula Rasa HealthCare, Inc. (NASDAQ:TRHC), a healthcare technology company optimizing medication safety, will release its second quarter 2018 operating results on [...]

Athenex Announces Axis Therapeutics Has Entered into a MOU with the Hong Kong Polytechnic University to Set Up a Joint Research Center on Cancer Immunotherapy

18/07/2018 - 15:00

BUFFALO, N.Y., July 18, 2018 (GLOBE NEWSWIRE) -- Athenex, Inc. (NASDAQ:ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of [...]

Tree of Knowledge Goes Public on the CSE Backed by Strong Management Team and Advisory Board -- CFN Media

18/07/2018 - 15:00

SEATTLE, July 18, 2018 (GLOBE NEWSWIRE) -- CFN Media Group (“CFN Media”), the leading agency and financial media network dedicated to the North American cannabis industry, today announced publication of an article [...]

Devonian Healthcare Group Reports its First ever Revenues: Key Financial Results for Quarter Ended April 30th, 2018

18/07/2018 - 14:45

QUEBEC CITY, July 18, 2018 (GLOBE NEWSWIRE) -- Devonian Health Group Inc. ( “Devonian” or the “Corporation” ) (TSX VENTURE:GSD), a clinical stage botanical pharmaceutical corporation focused on developing a unique [...]

Groupe Santé Devonian rapporte ses premiers revenus : Résultats Financiers clés pour le trimestre terminé le 30 avril 2018

18/07/2018 - 14:45

QUÉBEC, 18 juill. 2018 (GLOBE NEWSWIRE) -- Groupe Santé Devonian inc. ( « Devonian » ou la « Soci é t é » ) (TSX CROISSANCE:GSD), une société pharmaceutique botanique en stade avancé de développement axée sur l’ [...]

Altasciences Participates in Clinical Trial for Type 1 Diabetes Mellitus

18/07/2018 - 14:35

LAVAL, Quebec, July 18, 2018 (GLOBE NEWSWIRE) -- Altasciences is pleased to have partnered with Xeris Pharmaceuticals, a specialty pharmaceutical company leveraging its novel formulation technology platforms to develop [...]

Altasciences participe à un essai clinique sur le diabète sucré de type 1

18/07/2018 - 14:35

LAVAL, Québec, 18 juill. 2018 (GLOBE NEWSWIRE) -- Altasciences est heureuse d’avoir collaboré avec Xeris Pharmaceuticals, une entreprise pharmaceutique spécialisée qui utilise ses nouvelles plateformes technologiques de [...]

PositiveID Adds Listeria to Pathogens Detected by FireflyDX Onsite Detection Prototype

18/07/2018 - 14:31

FireflyDX prototype can also detect E. coli and other pathogens in minutes DELRAY BEACH, Fla., July 18, 2018 (GLOBE NEWSWIRE) -- PositiveID Corporation’s (“PositiveID” or “Company”) (OTC:PSID) ExcitePCR subsidiary today [...]

HMS Holdings Corp. To Report Second Quarter 2018 Financial and Operating Results

18/07/2018 - 14:30

IRVING, Texas, July 18, 2018 (GLOBE NEWSWIRE) -- HMS Holdings Corp. (Nasdaq:HMSY) today announced it will report second quarter 2018 financial and operating results at 7:30 am CT / 8:30 am ET on Friday, August 3, 2018. [...]

Hemostemix Announces First U.S. Patients Treated in Phase II Clinical Trial

18/07/2018 - 14:30

CALGARY, Alberta, July 18, 2018 (GLOBE NEWSWIRE) -- Hemostemix Inc. (“ Hemostemix ” or the “ Company ”) (TSX VENTURE:HEM) is pleased to announce that it has treated three additional patients including its first two [...]

Spectral Announces Successful Manufacturing Audit of Toray by the US FDA

18/07/2018 - 14:01

TORONTO, July 18, 2018 (GLOBE NEWSWIRE) -- Spectral Medical Inc. (“Spectral” or the “Company”) (TSX:EDT), a Phase III company developing the first treatment for patients with endotoxemic septic shock guided by a [...]

Cellectar Reports Positive Phase 2 Interim Data for CLR 131 in Relapsed/Refractory DLBCL Patients

18/07/2018 - 14:00

33% Overall Response Rate Observed in DLBCL Patient Cohort MADISON, Wis., July 18, 2018 (GLOBE NEWSWIRE) -- Cellectar Biosciences (Nasdaq:CLRB), a clinical stage biopharmaceutical company focused on the discovery, [...]